You are here: Industry Insights > Bevespi Aerosphere

News List

Bevespi Aerosphere approved in China for patients with COPD americanpharmaceuticalreview
May 26, 2020
AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
AZ’s new COPD inhaler Bevespi Aerosphere approved in EU pharmaphorum
December 24, 2018
AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients w worldpharmanews
September 26, 2017
Dr. Colin Reisner, Head of Respiratory, Global Medicines Development at AstraZeneca, said: "These positive results add to the strong established efficacy and safety profile of Bevespi Aerosphere in the treatment of patients with COPD.